XML 37 R11.htm IDEA: XBRL DOCUMENT
v3.22.4

Revenue Recognition | 12 Months Ended
--- | ---
Dec. 31, 2022
Revenue Recognition [Abstract] |
Revenue Recognition | REVENUE RECOGNITION We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. In 2022 less than 10% of our sales were recognized as services transferred over time. Refer to Note 1 for further discussion on our revenue recognition policies.
Segment Net Sales |  |  |  |  |
MedSurg and Neurotechnology: | 2022 |  | 2021 |  | 2020
Instruments | $ | 2,279 |  |  | $ | 2,111 |  |  | $ | 1,863 |
Endoscopy | 2,423 |  |  | 2,141 |  |  | 1,763 |
Medical | 3,031 |  |  | 2,607 |  |  | 2,524 |
Neurovascular | 1,200 |  |  | 1,188 |  |  | 973 |
Neuro Cranial | 1,376 |  |  | 1,214 |  |  | 972 |
Other | 302 |  |  | 277 |  |  | 250 |
| $ | 10,611 |  |  | $ | 9,538 |  |  | $ | 8,345 |
Orthopaedics and Spine: |  |  |  |  |
Knees | $ | 1,997 |  |  | $ | 1,848 |  |  | $ | 1,567 |
Hips | 1,413 |  |  | 1,342 |  |  | 1,206 |
Trauma and Extremities | 2,807 |  |  | 2,664 |  |  | 1,722 |
Spine | 1,146 |  |  | 1,167 |  |  | 1,047 |
Other | 475 |  |  | 549 |  |  | 464 |
| $ | 7,838 |  |  | $ | 7,570 |  |  | $ | 6,006 |
Total | $ | 18,449 |  |  | $ | 17,108 |  |  | $ | 14,351 |
United States Net Sales |  |  |  |  |
MedSurg and Neurotechnology: | 2022 |  | 2021 |  | 2020
Instruments | $ | 1,810 |  |  | $ | 1,637 |  |  | $ | 1,471 |
Endoscopy | 1,914 |  |  | 1,670 |  |  | 1,408 |
Medical | 2,422 |  |  | 2,007 |  |  | 1,910 |
Neurovascular | 446 |  |  | 451 |  |  | 381 |
Neuro Cranial | 1,135 |  |  | 988 |  |  | 801 |
Other | 297 |  |  | 273 |  |  | 247 |
| $ | 8,024 |  |  | $ | 7,026 |  |  | $ | 6,218 |
Orthopaedics and Spine: |  |  |  |  |
Knees | $ | 1,493 |  |  | $ | 1,351 |  |  | $ | 1,170 |
Hips | 896 |  |  | 822 |  |  | 777 |
Trauma and Extremities | 2,035 |  |  | 1,866 |  |  | 1,139 |
Spine | 836 |  |  | 831 |  |  | 764 |
Other | 354 |  |  | 425 |  |  | 387 |
| $ | 5,614 |  |  | $ | 5,295 |  |  | $ | 4,237 |
Total | $ | 13,638 |  |  | $ | 12,321 |  |  | $ | 10,455 |
International Net Sales |  |  |  |  |
MedSurg and Neurotechnology: | 2022 |  | 2021 |  | 2020
Instruments | $ | 469 |  |  | $ | 474 |  |  | $ | 392 |
Endoscopy | 509 |  |  | 471 |  |  | 355 |
Medical | 609 |  |  | 600 |  |  | 614 |
Neurovascular | 754 |  |  | 737 |  |  | 592 |
Neuro Cranial | 241 |  |  | 226 |  |  | 171 |
Other | 5 |  |  | 4 |  |  | 3 |
| $ | 2,587 |  |  | $ | 2,512 |  |  | $ | 2,127 |
Orthopaedics and Spine: |  |  |  |  |
Knees | $ | 504 |  |  | $ | 497 |  |  | $ | 397 |
Hips | 517 |  |  | 520 |  |  | 429 |
Trauma and Extremities | 772 |  |  | 798 |  |  | 583 |
Spine | 310 |  |  | 336 |  |  | 283 |
Other | 121 |  |  | 124 |  |  | 77 |
| $ | 2,224 |  |  | $ | 2,275 |  |  | $ | 1,769 |
Total | $ | 4,811 |  |  | $ | 4,787 |  |  | $ | 3,896 |
MedSurg and Neurotechnology MedSurg and Neurotechnology products include surgical equipment and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment, intensive care disposable products and clinical communication and workflow solutions (Medical), minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke (Neurovascular), a comprehensive line of products for traditional brain and open skull based surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products (Neuro Cranial) and other medical device products used in a variety of medical specialties. Substantially all MedSurg and Neurotechnology sales are recognized when a purchase order has been received and control has transferred. For certain Endoscopy, Instruments and Medical services, we may recognize sales over time as we satisfy performance obligations that may include an obligation to complete installation, provide training and perform ongoing services, generally performed within one year. Orthopaedics and Spine Orthopaedics and Spine products consist primarily of implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. Substantially all Orthopaedics sales are recognized when we have received a purchase order and appropriate notification the product has been used or implanted. Substantially all Spine sales are recognized when a purchase order has been received and control has transferred. For certain Orthopaedic products in the "other" category, we recognize sales at a point in time, as well as over time for performance obligations that may include an obligation to complete installation and provide training and ongoing services. Performance obligations are generally satisfied within one year. Contract Assets and Liabilities The nature of our products and services do not generally give rise to contract assets as we typically do not incur costs to fulfill a contract before a product or service is provided to a customer. Our costs to obtain contracts are typically in the form of sales commissions paid to employees or third-party agents. Certain sales commissions paid to employees prior to recognition of sales are recorded as contract assets. We expense sales commissions associated with obtaining a contract at the time of the sale or as incurred as the amortization period is generally less than one year. These costs have been presented within selling, general and administrative expenses. On December 31, 2022 contract assets recorded in our Consolidated Balance Sheets were not significant. Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $741 and $529 on December 31, 2022 and 2021. Changes in contract liabilities during the year were as follows:
| 2022
Beginning contract liabilities | $ | 529 |
Revenue recognized from beginning of year contract liabilities | (329) |
Contract liabilities acquired | 80 |
Net advance consideration received during the period | 461 |
Ending contract liabilities | $ | 741 |

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI https://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration